Services

recombinant exosomes

We have developed a platform technology to engineer the CD81 extracellular loop domain on EVs to select binders to specific cell surface proteins. Proof of Principle has been successfully achieved for recombinant extracellular vesicles targeting laminin and EGFR specifically. This technology will allow the development of a broad range of new therapeutic applications and targeting strategies in the extracellular vesicle space.

General information

EV platform technology to select specific binders:  in cooperation with BOKU (University of Natural Resources and Life Sciences Vienna) and ACIB (Austrian Center of Industrial Biotechnolgy), Evercyte has generated a technology platform for the development of cell/tissue targeting extracellualr vesicles. This platform is based on the generation of a surface display library by randomization of an extracellular loop of EV surface proteins.

What we need: soluble, fluorescently labeled antigen-of-interest for selection of binding CD81 mutants for targeting EVs towards cells carrying the specific antigen-of-interest.
Timelines:
around 5-8 months to deliver specific antigen binding EVs.

Recent example – generation of tumor-targeting EVs

In order to improve tumor targeting, Evercyte and MDimune have entered a collaboration where Evercyte’s novel and proprietary technology platform will be combined with MDimune´s highly expandable BioDrone® platform for the generation of targeted extracellular vesicles (EVs). Thereby identified high-affinity binders to specific tumor antigens will be used to develop novel drug-targeting vehicles.

Recent example - targeting laminin

Recombinant extracellular vesicles targeting laminin as proof-of-principle enhances cellular uptake of EVs significantly. Please have a look at our new publication "An engineered CD81-based combinatorial library for selecting recombinant binders to cell surface proteins: Laminin binding CD81 enhances cellular uptake of extracellular vesicles." J Extracell Vesicles. 2021;10:e12139.

https://pubmed.ncbi.nlm.nih.gov/34514736/

This work was performed in cooperation with ACIB, University of Natural Resources and Life Sciences, Vienna and the Ludwig Boltzmann Institute for Traumatology – the research center in collaboration with AUVA (LBI Trauma).

Leaflets - extracellular vesicles

Extracellular vesicles from telomerized cells

 

Selected publications

Vogt S, Bobbili MR, Stadlmayr G, Stadlbauer K, Kjems J, Rüker F, Grillari J, Wozniak-Knopp G (2021). An engineered CD81-based combinatorial library for selecting recombinant binders to cell surface proteins: Laminin binding CD81 enhances cellular uptake of extracellular vesicles. J Am Soc Nephrol. 2011 Jul;22(7):1221-8. https://pubmed.ncbi.nlm.nih.gov/33717998/

Print Friendly, PDF & Email
get in contact

Related Services

establishment of stable cell lines for proudction of extracellular vesicles

read more

P-MSC/TERT308

Placental amnion-derived mesenchymal stem cells

read more

MSCs for production of clinical grade extracellular vesicles

send us specific request

Customer Reviews

“I have had the pleasure of working with Evercyte for the last few years. We continually rely on Evercyte because of the high-quality data that they produce, their diligent responsiveness, and their excellent customer service.”

 

Josh Garlich, Senior Research Scientist, Apellis Pharmaceuticals, Inc.

"Cytonus has been working with Evercyte from many years as they are a trusted partner and have always delivered the highest quality cell lines to advance our platform.  We routinely draw on their expertise to meet cellular engineering challenges and they have not disappointed."

Remo Moomiaie-Qajar, Cytonus Therapeutics, Inc.

all about our
EV cell factories

read more
Print Friendly, PDF & Email
get in contact

Related Services

establishment of stable cell lines for proudction of extracellular vesicles

read more

WJ-MSC/TERT273

Wharton´s Jelly derived mesenchymal stem cells

read more

MSCs for production of clinical grade extracellular vesicles

send us specific request

Customer Reviews

“I have had the pleasure of working with Evercyte for the last few years. We continually rely on Evercyte because of the high-quality data that they produce, their diligent responsiveness, and their excellent customer service.”

 

Josh Garlich, Senior Research Scientist, Apellis Pharmaceuticals, Inc.

"Cytonus has been working with Evercyte from many years as they are a trusted partner and have always delivered the highest quality cell lines to advance our platform.  We routinely draw on their expertise to meet cellular engineering challenges and they have not disappointed."

Remo Moomiaie-Qajar, Cytonus Therapeutics, Inc.

all about our
EV cell factories

read more

Related Products

adipose-derived mesenchymal stem cells ASC/TERT300 for production of extracellular vesicles

EV cell factory for production of clinical grade extracellular vesicles

read more

Related Services

establishment of stable cell lines for production of extracellular vesicles / exosomes for clinical application

specific request

Customer Reviews

“I have had the pleasure of working with Evercyte for the last few years. We continually rely on Evercyte because of the high-quality data that they produce, their diligent responsiveness, and their excellent customer service.”

 

Josh Garlich, Senior Research Scientist, Apellis Pharmaceuticals, Inc.

"Cytonus has been working with Evercyte from many years as they are a trusted partner and have always delivered the highest quality cell lines to advance our platform.  We routinely draw on their expertise to meet cellular engineering challenges and they have not disappointed."

Remo Moomiaie-Qajar, Cytonus Therapeutics, Inc.

Print Friendly, PDF & Email